|
1
|
Smith MA, Ungerleider RS, Horowitz ME and
Simon R: Influence of doxorubicin dose intensity on response and
outcome for patients with osteogenic osteosarcoma and Ewing’s
sarcoma. J Natl Cancer Inst. 83:1460–1470. 1991.PubMed/NCBI
|
|
2
|
Lewis IJ, Nooij MA, Whelan J, et al; MRC
BO06 and EORTC 80931 collaborators; European Osteosarcoma
Intergroup. Improvement in histologic response but not survival in
osteosarcoma patients treated with intensified chemotherapy: a
randomized phase III trial of the European Osteosarcoma Intergroup.
J Natl Cancer Inst. 99:112–128. 2007. View Article : Google Scholar
|
|
3
|
Graf N, Winkler K, Betlemovic M, et al:
Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin
Oncol. 12:1443–1451. 1994.PubMed/NCBI
|
|
4
|
Delepine N, Delepine G, Bacci G, et al:
Influence of methotrexate dose intensity on outcome of patients
with high grade osteogenic osteosarcoma. Analysis of the
literature. Cancer. 78:2127–2135. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lewis VO, Raymond K, Mirza AN, Lin P and
Yasko AW: Outcome of postradiation osteosarcoma does not correlate
with chemotherapy response. Clin Orthop Related Res. 450:60–66.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goldsby R, Burke C, Nagarajan R, et al:
Second solid malignancies among children, adolescents, and young
adults diagnosed with malignant bone turmors after 1976: follow up
of a Children’s Oncology Group cohort. Cancer. 113:2597–2604.
2008.PubMed/NCBI
|
|
8
|
Mansky P, Arai A, Stratton P, et al:
Treatment late effects in long-term survivors of pediatric sarcoma.
Pediatr Blood Cancer. 48:192–199. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng A, Kallio A and Härkönen P:
Tamoxifen-induced rapid death of MCF-7 breast cancer cells is
mediated via extracellularly signal-regulated kinase signaling and
can be abrogated by estrogen. Endocrinology. 148:2764–2777. 2007.
View Article : Google Scholar
|
|
10
|
Tan CK, Chow PK, Findlay M, et al: Use of
tamoxifen in hepatocellular carcinoma: a review and paradigm shift.
J Gastroenterol Hepatol. 15:725–729. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Emst M, Parker MG and Rodan GA: Functional
estrogen receptors in osteoblastic cells demonstrated by
transfection with a reporter gene containing an estrogen response
element. Mol Endocrinol. 5:1597–1606. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carmichael J, DeGraff WG, Gazdar AF, et
al: Evaluation of a tetrazolium-based semiautomated colorimetric
assay: assessment of chemosensitivity testing. Cancer Res.
47:936–942. 1987.PubMed/NCBI
|
|
13
|
Braidman IP, Davennport LK, Carter DH, et
al: Preliminary in situ identification of estrogen target cells in
bone. J Bone Miner Res. 10:74–80. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Walker MJ, Chaudhuri PK, Beattie CW and
Das Gupta TK: Steroid receptors in malignant skeletal tumors.
Cancer. 45:3004–3007. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stedman KE, Moore GE and Morgan RT:
Estrogen receptor proteins in diverse human tumors. Arch Surg.
115:244–248. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen FP, Hsu T, Hu CH, Wang WD, Wang KC
and Teng LF: Expression of estrogen receptors alpha and beta in
human osteoblasts: identification of exon-2 deletion variant of
estrogen receptor beta in postmenopausal women. Chang Gung Med J.
27:107–115. 2004.PubMed/NCBI
|
|
17
|
Dohi O, Hatori M, Suzuki T, et al: Sex
steroid receptors expression and hormone-induced cell proliferation
in human osteosarcoma. Cancer Sci. 99:518–523. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Monroe DG, Secreto FJ, Subramaniam M, Getz
BJ, Khosla S and Spelsberg TC: Estrogen receptor alpha and beta
heterodimers exert unique effects on estrogen- and
tamoxifen-dependent gene expression in human U2OS osteosarcoma
cells. Mol Endocrinol. 19:1555–1568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Solakidi S, Psarra AM and Sekeris CE:
Differential subcellular distribution of estrogen receptor
isoforms: localization of ERalpha in the nucleoli and ERbeta in the
mitochondria of human osteosarcoma SaOS-2 and hepatocarcinoma HepG2
cell lines. Biochim Biophys Acta. 1745:382–392. 2005. View Article : Google Scholar
|
|
20
|
Luo XH and Liao EY: Effects of estriol on
the proliferation and differentiation of human osteoblastics MG63
cells. Endocr Res. 29:343–351. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Berman E, Adams M, Duiguo-Osterndorf R,
Godfrey L, Clarkson B and Andreeff M: Effect of tamoxifen on cell
lines displaying the multidrug-resistant phenotype. Blood.
77:818–825. 1991.PubMed/NCBI
|
|
22
|
Kang Y and Perry RR: Modulatory effects of
tamoxifen and recombinant human alpha-interferon on doxorubicin
resistance. Cancer Res. 53:3040–3045. 1993.PubMed/NCBI
|
|
23
|
Kirk J, Houlbrook S, Stuart NSA, Stratford
IJ, Harris AL and Carmichael J: Differential modulation of
doxorubicin toxicity to multidrug and intrinsically drug resistant
cell lines by anti-oestrogens and their major metabolites. Br J
Cancer. 67:1189–1195. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
O’Brian CA, Liskamp RM, Solomon DH and
Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer
Res. 45:2462–2465. 1985.PubMed/NCBI
|
|
25
|
Lam HY: Tamoxifen is a calmodulin
antagonist in the activation of cAMP phosphodiesterase. Biochem
Biophys Res Commun. 118:27–32. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huynh TH, Tetenes E, Wallace L and Pollak
M: In vivo inhibition of insulin-like growth factor I gene
expression by tamoxifen. Cancer Res. 53:1727–1730. 1993.PubMed/NCBI
|
|
27
|
Noguchi S, Motomura K, Inaji H, Imalka S
and Koyama H: Down-regulation of transforming growth factor-alpha
by tamoxifen in human breast cancer. Cancer. 72:131–136. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Butta A, MacLennan K, Flanders KC, Sacks
NP, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M,
et al: Induction of transforming growth factor beta 1 in human
breast cancer in vivo following tamoxifen treatment. Cancer Res.
52:4261–4264. 1992.PubMed/NCBI
|
|
29
|
Baral E, Nagy E and Berczi I: Modulation
of natural killer cell-mediated cytotoxicity by tamoxiefn and
estradiol. Cancer. 75:591–599. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Couldwell WT, Hinton DR, He S, Chen TC,
Sebat I, Weiss MH and Law RE: Protein kinase C inhibitors induce
apoptosis in human malignant glioma cell lines. FEBS Lett.
345:43–46. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gelmann EP: Tamoxifen induction of
apoptosis in estrogen receptor-negative cancers: New tricks for an
old dog. J Natl Cancer Inst. 88:224–226. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Clarke R, van den Berg HW and Murphy RF:
Reduction of the membrane fluidity of human breast cancer cells by
tamoxifen and 17 beta-estradiol. J Natl Cancer Inst. 82:1702–1705.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Del Prete SA, Maurer LH, O’Donnel J,
Forcier RJ and LeMarbre P: Combination chemotherapy with cisplatin,
carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
Cancer Treat Rep. 68:1403–1405. 1984.PubMed/NCBI
|
|
34
|
Cocconi G, Bella M, Calabresi F, Tonato M,
Canaletti R, Boni C, Buzzi F, Ceci G, Corgna E, Costa P, et al:
Treatment of metastatic malignant melanoma with dacarbazine plus
tamoxifen. N Engl J Med. 327:516–523. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vertosick FT Jr, Selker RG, Pollack IF and
Arena V: The treatment of intracranial malignant glioma using
orally administered tamoxifen therapy: preliminary results in a
series of ‘failed’ patients. Neurosurgery. 30:897–903.
1992.PubMed/NCBI
|
|
36
|
Narasimhan P: Tamoxifen in the treatment
of refractory lymphoma. N Engl J Med. 311:1258–1259. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ferguson PJ, Brisson AR, Koropatnick J and
Vincent MD: Enhancement of cytotoxicity of natural product drugs
against multidrug resistant variant cell lines of human head and
neck squamous cell carcinoma and breast carcinoma by tesmilifene.
Cancer Lett. 274:279–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Singh MN, Martin-Hirsch PL and Martin FL:
The multiple applications of tamoxifen: an example pointing to SERM
modulation being the aspirin of the 21st century. Med Sci Monit.
14:RA144–RA148. 2008.PubMed/NCBI
|
|
39
|
Kang Y, Cortina R and Perry RR: Role of
c-myc in tamoxifen induced apoptosis in estrogen-independent breast
cancer cells. J Natl Cancer Inst. 88:279–284. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Incles CM, Schultes CM, Kelland LR and
Neidle S: Acquired cellular resistance to flavopiridol in a human
colon carcinoma cell line involves up-regulation of the telomerase
catalytic subunit and telomere elongation. Sensitivity of resistant
cells to combination treatment with a telomerase inhibitor 1. Mol
Pharmacol. 64:1101–1108. 2003. View Article : Google Scholar
|
|
41
|
Cory S and Adams JM: Killing cancer cells
by flipping the Bcl-2/Bax switch. Cancer Cell. 8:5–6. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Korsmeyer SJ, Shutter JR, Veis DJ, et al:
Bcl-2/Bax: a rheostat that relgulates an anti-oxidant pathway and
cell death. Semin Cancer Biol. 4:327–332. 1993.PubMed/NCBI
|
|
43
|
Agostinis P, Vantieghem A, Merlevede W and
de Witte PA: Hypericin in cancer treatment: more light on the way.
Int J Biochem Cell Biol. 34:221–241. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mandlekar S and Kong AN: Mechanism of
tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar
|
|
45
|
Cheng AL, Chuang SE, Fine RL, Yeh KH, Liao
CM, Lay JD and Chen DS: Inhibition of the membrane translocation
and activation of protein kinase C, and potentiation of
doxorubicin-induced apoptosis of hepatocellular carcinoma cells by
tamoxifen. Biochem Pharmacol. 55:523–531. 1998. View Article : Google Scholar
|
